Roy Lee Sutliff, PhD
Associate Professor of Medicine
Department of Medicine
Office: VAMC 12C 104 Ext: 7053
Dr. Sutliff completed a BS in Biochemistry at Temple University in Philadelphia in 1990. He completed his PhD training in Pharmacology at the Medical College of Pennsylvania, now Drexel University, in 1995. His thesis focused on characterizing the cardiovascular effects of cocaine in pregnant rabbits. He completed a postdoctoral fellowship at the University of Cincinnati under Dr. Richard J. Paul. While there he learned how to generate and characterize cardiovascular pathophysiology in gene-altered mouse models. After four years as a Research Assistant Professor in the Department of Pathology at Emory University, he joined the Department of Medicine, Division of Pulmonary, Allergy and Critical Care in April of 2003 and was promoted to Associate Professor in the Department of Medicine in 2011. Dr. Sutliff also serves as the Faculty Associate for International Programs at the Laney Graduate School. He is very active in the Molecular Systems Pharmacology Program at Emory and serves on its Executive Committee.
Dr. Sutliff has maintained a funded research program that broadly focuses on the role of oxidative stress in the development of cardiovascular and pulmonary diseases. His laboratory collaborates extensively with that of Dr. Mike Hart on the role of PPARg in pulmonary hypertension and cardiovascular disease. The laboratory uses an integrative approach on a wide range of projects involving, but not limited to whole animal physiology, understanding the effects of these models on blood pressure and/or pulmonary function, isolated tissue studies examining vascular function, and cellular preparations to examine cell-type specific mechanisms. Other ongoing collaborations involve examining everything from the effects of long-term blood storage on vascular function, to the effects of HIV-1 on TB co-infection, to mechanisms underlying the development HIV-associated cardiovascular disease, to the development of novel rho kinase inhibitors for the treatment of pulmonary hypertension.